Key Players
Competitive Landscape
Business models vary significantly, ranging from condition-specific medical nutrition to broad clinical ONS platforms and modular protein products. Abbott, Nestle Health Science, and Danone Nutricia offer pulmonary-specific product designs. Fresenius Kabi, Meiji Holdings, and B. Braun compete much more through clinical ONS breadth and high-energy or high-protein formats. Medtrition adds a highly concentrated modular-protein model, while Victus participates through broader complete and specialized nutrition. This reality makes portfolio comparison vastly more useful than a single, linear supplier ranking.[13][14][15][16][17][18][19][20]
Entry and switching barriers are deeply clinical as well as commercial. Buyers require concrete evidence of medical-nutrition suitability and patient tolerability. Serving-volume practicality, supply continuity, and strict fit with professional supervision also heavily affect qualification. Hospital formularies and institutional purchasing can easily lock in repeat use once a product is standardized. Post-discharge continuation then depends entirely on retail or homecare access and online availability. Recent company actions clearly show heavy investment in compact formats and medical-nutrition platforms. Ultimately, professional engagement matters far more than a uniform industry move toward a single macronutrient formula.[13][14][15][16][17][18][22]
Company developments mapped to drivers, trends and opportunities (2026-2036)
Table 6: Dated company entries mapped to drivers, trends and opportunities for the Pulmonary Rehabilitation Nutrition Market (qualitative), 2026 to 2036
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| May 2024: Danone acquired Functional Formularies, adding a U.S. whole-food tube-feeding business to its medical-nutrition portfolio. | Need for clinically supervised nutrition across care settings. | Specialized-nutrition platforms are broadening beyond single formula types. | Use a wider medical-nutrition platform to support transitions between hospital and home where product fit is documented. |
| November 2023: Danone launched Fortimel adult medical nutrition in China for post-surgery and chronic-disease recovery. | Post-discharge malnutrition creates a continuation need after hospital care. | Adult medical nutrition is moving across inpatient and at-home pathways. | Build discharge-to-home access for medically supervised products without treating all recovery nutrition as pulmonary-specific. |
Other profiled participants add distinctly different capabilities. Abbott and Nestle Health Science document lower-carbohydrate pulmonary formulas. Meiji and B. Braun document compact or high-energy clinical nutrition. Medtrition adds concentrated protein, while Victus provides broader complete and specialized nutrition.[13][14][17][18][19][20]
The competitive implication is that buyers can cleanly separate respiratory-specific formulation from volume tolerance and protein density. Portfolio breadth and channel continuity serve as additional dimensions.
How are profiled companies positioned differently in pulmonary rehabilitation nutrition? Abbott (Pulmocare), Nestle Health Science (Nutren Pulmonary), and Danone Nutricia (Respifor) possess clearly documented pulmonary-specific products. Fresenius Kabi and B. Braun operate as broader clinical-nutrition suppliers, while Meiji Holdings and Medtrition add highly compact or protein-dense formats. Victus is documented primarily as a broader specialized-nutrition participant.[13][14][15][16][17][18][19][20]
What qualification or purchasing requirements matter most for buyers? Rehab centers and hospitals must rigorously verify medical-nutrition status and intended use. Nutrient density, serving volume, and patient tolerability also matter immensely. Supply continuity ultimately determines whether an initially suitable product can support long-term repeat use. Abbott and Nestle Health Science provide excellent product-specific medical use information. Danone Nutricia and Fresenius Kabi do as well. Other participants require much closer matching to the specific pulmonary rehabilitation use case.[13][14][15][16]
Which product and application capabilities differentiate suppliers? Abbott and Nestle Health Science document high-fat, lower-carbohydrate pulmonary formulas. Danone Nutricia documents a 125 ml COPD-specific high-protein ONS, while Fresenius Kabi offers 2 kcal/ml high-protein ONS that explicitly lists COPD among its indications. Meiji Holdings and Medtrition are highly differentiated by their ability to deliver compact calorie or protein density.[13][14][15][16][17][18]
How does geographic reach influence supplier selection? Danone Nutricia and Fresenius Kabi document extensive medical-nutrition activity across multiple global regions, while Medtrition states its products are used in more than 50 countries. Meiji Holdings is much more Japan-centered in its clinical nutrition footprint, and Victus documents strong U.S. plus Latin American channels. Product availability should still be verified locally for every profiled company.[17][18][19][22][24][25]
Representative Company Overview
Table 7: Representative company overview for the Pulmonary Rehabilitation Nutrition Market (qualitative)
| Company | Positioning | Product and Channel Activity |
|---|---|---|
| Danone Nutricia (Respifor) | Pulmonary-specific low-volume ONS plus a broad medical-nutrition platform. | September 2023: Danone announced a EUR 50 million expansion of its Opole, Poland facility to increase adult medical-nutrition manufacturing capability. |
| Meiji Holdings | Compact high-nutrition formats with hospital and small-volume use cases. | 2021: Meiji launched Mei Balance Gyutto Mini for hospitals at 100 ml and 200 kcal; the 2025 securities report documents continued expansion of the compact line. |
Research Methodology
Company mapping covers the profiled companies and their product scope, channel models, geographic availability, and corporate activity. It includes pulmonary-specific products, broader clinical nutrition, compact formats, and modular protein portfolios.
